Premium
P4‐236: Does concomitant treatment with cholinesterase inhibitors or memantine affect cerebrolysin treatment's efficacy in Alzheimer disease? Results from the Argentinean cerebrolysin registry
Author(s) -
Previgliano Ignacio,
Kremer Janus,
Tiezzi Gerardo,
Rojas Galeno,
Tozzola Marco,
Albanese Gustavo,
Bukler Miryam,
Bosch Mauricio,
Andersson Alejandro,
Klein Ricardo,
Torres Marta,
Ponteville Christiane
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.2261
Subject(s) - cerebrolysin , memantine , medicine , concomitant , cholinesterase , randomized controlled trial , statistical significance , morphea , adverse effect , dementia , disease , biopsy
O (donepezil) 21 9 0 30 21.16 1.89 I (rivastigmine) 25 9 2 36 17.42 1.73 A (gallantamine) 9 3 0 12 20.66 2 E (memantine) 14 3 1 18 18.10 0.66 OME 40 1 2 43 18.52 3.75 IME 21 9 1 31 15.85 2.26 AME 5 2 0 7 17.83 3 e (cerebrolysin) 20 4 1 25 19.47 4.68 otal 155 40 7 202 18.54 2.76 Diana Pollock, Vikram Atit, George Brewer, Steven Kanzer, Lara Guzman, David Newsome, Ptak Alzheimer’s Research Center, Clearwater, Florida, United States; Atit Neurology Institute, Holiday, Florida, United States; Adeona, Ann Arbor, Michigan, United States.